scholarly journals Magnetic Particle Imaging-Guided Heating in Vivo Using Gradient Fields for Arbitrary Localization of Magnetic Hyperthermia Therapy

ACS Nano ◽  
2018 ◽  
Vol 12 (4) ◽  
pp. 3699-3713 ◽  
Author(s):  
Zhi Wei Tay ◽  
Prashant Chandrasekharan ◽  
Andreina Chiu-Lam ◽  
Daniel W. Hensley ◽  
Rohan Dhavalikar ◽  
...  
Nanoscale ◽  
2020 ◽  
Vol 12 (35) ◽  
pp. 18342-18355
Author(s):  
James Wells ◽  
Shailey Twamley ◽  
Aparna Sekar ◽  
Antje Ludwig ◽  
Hendrik Paysen ◽  
...  

Magnetic nanoparticle localisation, remote thermometry and focussed hyperthermia therapy application using Lissajous scanning magnetic particle imaging.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Azadeh Mohtashamdolatshahi ◽  
Harald Kratz ◽  
Olaf Kosch ◽  
Ralf Hauptmann ◽  
Nicola Stolzenburg ◽  
...  

Abstract Magnetic Particle Imaging (MPI) is a new imaging modality, which maps the distribution of magnetic nanoparticles (MNP) in 3D with high temporal resolution. It thus may be suited for cardiovascular imaging. Its sensitivity and spatial resolution critically depend on the magnetic properties of MNP. Therefore, we used novel multicore nanoparticles (MCP 3) for in-vivo MPI in rats and analyzed dose requirements, sensitivity and detail resolution. 8 rats were examined using a preclinical MPI scanner (Bruker Biospin GmbH, Germany) equipped with a separate receive coil. MCP 3 and Resovist were administered intravenously (i.v.) into the rats’ tail veins at doses of 0.1, 0.05 and 0.025 mmol Fe/kg followed by serial MPI acquisition with a temporal resolution of 46 volumes per second. Based on a qualitative visual scoring system MCP 3–MPI images showed a significantly (P ≤ 0.05) higher image quality than Resovist-MPI images. Morphological features such as vessel lumen diameters (DL) of the inferior vena cava (IVC) and abdominal aorta (AA) could be assessed along a 2-cm segment in mesenteric area only after administration of MCP 3 at dosages of 0.1, 0.05 mmol Fe/kg. The mean DL ± SD estimated was 2.7 ± 0.6 mm for IVC and 2.4 ± 0.7 mm for AA. Evaluation of DL of the IVC and AA was not possible in Resovist-MPI images. Our results show, that MCP 3 provide better image quality at a lower dosage than Resovist. MCP 3-MPI with a clinically acceptable dose of 0.05 mmol Fe/kg increased the visibility of vessel lumens compared to Resovist-based MPI towards possible detection of vascular abnormalities such as stenosis or aneurysms, in vivo.


Theranostics ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 2965-2981 ◽  
Author(s):  
Prashant Chandrasekharan ◽  
Zhi Wei Tay ◽  
Daniel Hensley ◽  
Xinyi Y Zhou ◽  
Barry KL Fung ◽  
...  

Theranostics ◽  
2018 ◽  
Vol 8 (13) ◽  
pp. 3676-3687 ◽  
Author(s):  
Zhi Wei Tay ◽  
Prashant Chandrasekharan ◽  
Xinyi Yedda Zhou ◽  
Elaine Yu ◽  
Bo Zheng ◽  
...  

Author(s):  
Angelie Rivera-Rodriguez ◽  
Lan B. Hoang-Minh ◽  
Andreina Chiu-Lam ◽  
Nicole Sarna ◽  
Leyda Marrero-Morales ◽  
...  

ABSTRACTAdoptive cellular therapy (ACT) is a potent strategy to boost the immune response against cancer. ACT is an effective treatment for blood cancers, such as leukemias and lymphomas, but faces challenges treating solid tumors and cancers in locations like the brain. A critical step for success of ACT immunotherapy is achieving efficient trafficking of T cells to solid tumors, and the non-invasive and quantitative tracking of adoptively transferred T cell biodistribution would accelerate its development. Here, we demonstrate the use of Magnetic Particle Imaging (MPI) to non-invasively track ACT T cells in vivo. Labeling T cells with the superparamagnetic iron oxide nanoparticle tracer ferucarbotran did not affect T cell viability, phenotype, or cytotoxic function in vitro. Following ACT, ferucarbotran-labeled T cells were detected and quantified using MPI ex vivo and in vivo, in a mouse model of invasive brain cancer. Proof-of-principle in vivo MPI demonstrated its capacity to detect labeled T cells in lungs and liver after intravenous administration and to monitor T cell localization in the brain after intraventricular administration. Ex vivo imaging using MPI and optical imaging suggests accumulation of systemically administered ferucarbotran-labeled T cells in the brain, where MPI signal from ferucarbotran tracers and fluorescently tagged T cells were observed. Ex vivo imaging also suggest differential accumulation of nanoparticles and viable T cells in other organs like the spleen and liver. These results support the use of MPI to track adoptively transferred T cells and accelerate the development of ACT treatments for brain tumors and other cancers.


2020 ◽  
Author(s):  
Gang Ren ◽  
Jeff M. Gaudet ◽  
Marco Gerosa ◽  
Yanrong Zhang ◽  
James Mansfield ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document